Peptides in men and women: what the differences actually are

TL;DR

• The biggest sex difference here is evidentiary, not pharmacological - women of childbearing potential were formally excluded from most early-phase US trials from the late 1970s until policy reversed in 1993.
• Inclusion never became analysis. Sex-disaggregated results are often unreported or underpowered, so "no difference found" frequently means "not adequately looked for".
• Oral oestrogen attenuates hepatic IGF-1 generation via first-pass metabolism - so IGF-1 doesn't mean the same thing in a woman on oral oestrogen; transdermal has a far smaller effect.
• GLP-1 obesity trials inverted the historical pattern, enrolling roughly two-thirds to three-quarters women - the rare area where the female dataset is the larger one.
• Delayed gastric emptying can affect absorption of oral medications including contraceptives - at least one agent in the class carries a specific label warning.
• Pregnancy and breastfeeding safety data is absent for essentially every compound in this category - and absence of data is not evidence of safety.

Educational content, not medical advice. This article contains no doses, no dose figures and no sex-based dosing guidance of any kind. Any decision about therapy belongs with a prescribing clinician.

---

The question people ask, and the question worth asking

The question usually arrives in a simple form: do peptides work differently in women? It sounds like a pharmacology question with a pharmacology answer.

For a small number of compounds it is. For most of them the question is answerable only in the sense that any question is answerable when the data does not exist - which is to say, honestly, with "we do not know, and here is precisely why we do not know."

That is not evasion, and it is not a lesser article than the confident version. The structure of the evidence base is the single most useful thing a reader can understand here, because it determines how much weight to place on every claim that follows, including claims made confidently by people selling something. This article covers the evidence gap first, then the documented physiological differences, then the specific places where sex differences in this space are genuinely established - and it is explicit about which of those is which.

If you are new to the category, what are peptides and peptides explained cover the fundamentals this article assumes.

The evidence gap is the headline, not the footnote

How the exclusion happened

Between the late 1970s and the early 1990s, women of childbearing potential were formally excluded from most early-phase clinical trials in the United States. The exclusion was framed as protective - a response to the thalidomide and diethylstilbestrol tragedies, and to the risk of foetal exposure in trials of unproven compounds. Whatever its intent, the effect was structural: the foundational pharmacokinetic and safety data for a very large number of drugs was generated in male subjects and then generalised to everyone.

That policy was formally reversed. United States regulatory guidance changed in 1993 to permit and encourage the inclusion of women in early-phase studies, and legislation in the same period required the inclusion of women in federally funded clinical research along with analysis by sex. This is documented regulatory history, not an interpretation.

Why the gap did not close

Reversing a policy does not retroactively generate data, and three things kept the gap open.

Legacy data persists. Drugs approved on male-derived pharmacokinetic data did not get re-characterised. The original datasets remain the basis of what is known about them.

Inclusion is not the same as analysis. Enrolling women produces a mixed-sex trial. Learning anything about sex differences requires the trial to be powered for a sex-stratified comparison and to actually report one. Reviews of published trials continue to find that sex-disaggregated results are frequently not reported, and where they are reported, subgroup analyses are often underpowered - meaning a real difference could exist and the study would be unable to detect it. "No significant difference between men and women" and "adequately demonstrated no difference" are not the same finding, and the distinction is routinely lost in summary.

The menstrual cycle is usually ignored. Cyclical variation in sex hormones introduces a within-person variable that affects some pharmacokinetic and physiological parameters. Most trial designs do not control for cycle phase, do not record it, and therefore cannot account for it. This is a known methodological limitation of the field rather than a fringe concern.

Why one regulatory precedent matters here

The clearest illustration that this is a real problem with real consequences is the sleep medication zolpidem. Post-approval data indicated slower clearance in women and higher morning blood concentrations, with implications for next-day impairment, and in 2013 the FDA revised the recommended dosing downward for women - the first time the agency had issued sex-specific dosing guidance for a widely used drug.

The point of citing that here is entirely methodological. It is evidence that sex-flat dosing was, in at least one well-studied case, demonstrably wrong, and that it took years of post-marketing data to establish. It is not guidance. This article gives no dose figures and no sex-based adjustment for anything, and no reader should extrapolate from zolpidem to any other compound - the finding was specific to that drug's metabolism, and the direction of a sex difference is not predictable in advance.

The physiological differences that are established in general pharmacology

Separate from the evidence gap, general pharmacology has documented a set of average differences between men and women that would be expected to influence how any injectable or systemically absorbed compound behaves. These are population averages with substantial individual overlap - an important qualification, because they describe distributions, not people.

Body composition. Women on average carry a higher proportion of body fat and a lower proportion of fat-free mass than men of the same weight, with a different pattern of adipose distribution. This affects volume of distribution, and it affects it in opposite directions depending on the compound: lipophilic compounds distribute more widely into adipose tissue, while water-soluble compounds distribute into a proportionally smaller aqueous compartment. Peptides are generally hydrophilic and large, which changes the picture again - most do not distribute into fat the way small lipophilic molecules do - but body composition still influences distribution volume and clearance.

Average body weight, and weight-flat dosing. Many products are supplied and administered at a fixed amount irrespective of body weight. Where average body weight differs systematically between groups, a fixed amount delivers a systematically different exposure per kilogram. This is a genuine and well-recognised methodological issue in pharmacology, and it applies to men at the extremes of body weight as much as it applies to women. It is stated here as a principle. It is not an instruction, and the appropriate response to it is a conversation with a prescriber, not an adjustment made by the reader.

Hepatic metabolism. Activity of several drug-metabolising enzymes differs by sex on average. CYP3A4 activity is reported as somewhat higher in women; CYP1A2 and CYP2E1 activity somewhat lower. Peptides are largely cleared by peptidase degradation rather than by cytochrome P450 metabolism, which limits the direct relevance for many of them - but it is highly relevant for co-administered medications, and for the small-molecule agents that increasingly sit alongside peptides in the same treatment conversations.

Renal clearance. Glomerular filtration rate is lower on average in women, much of which is accounted for by body size, and renal handling matters for the clearance of smaller peptides and peptide fragments.

Gastric emptying. Gastric emptying is on average slower in women. This is directly relevant to orally administered agents and to any drug whose effects are mediated through gastrointestinal motility - a point that becomes concrete in the GLP-1 section below.

Adverse-event reporting. Pharmacovigilance data consistently shows women reporting adverse drug reactions at higher rates than men across many drug classes. The interpretation of that finding is genuinely contested - it may reflect differences in exposure, in underlying pharmacokinetics, in health-seeking and reporting behaviour, in prescribing patterns, or some combination. It is a robust observation with an unresolved explanation, and it should be presented that way rather than as evidence of greater biological susceptibility.

Where sex differences in this space are genuinely documented

Three areas have enough data to say something substantive. They are worth separating carefully from everything else.

GLP-1 receptor agonists - the pattern reversed

The obesity trials in this class are an unusual case: they enrolled majority-female populations, in the region of two-thirds to three-quarters of participants in several of the major programmes, which inverts the historical pattern rather than repeating it. That makes this one of the few areas where the female data is the larger dataset.

What has been reported from those trials and their subgroup analyses:

• Average percentage weight loss has generally been greater in women than in men across the major obesity programmes. The size of the difference varies by trial and agent, and this is a difference in group averages, not a prediction for any individual.
• Gastrointestinal adverse events - nausea, vomiting - have generally been reported more frequently by women. This is consistent with the wider pharmacovigilance pattern and with sex differences in baseline gastric emptying, though neither of those establishes the mechanism.
• Baseline differences confound the comparison. Men and women in these trials differed in starting weight, body composition and comorbidity profile. Some of the difference in percentage weight loss is arithmetic - the same absolute loss is a larger percentage of a smaller starting weight - and disentangling that from a genuine difference in drug response requires analysis that has not been uniformly done.

A separate and practically important point for women: delayed gastric emptying can affect the absorption of oral medications, including oral contraceptives, and labelling for at least one agent in the class carries a specific warning on this. That is a documented interaction, it has obvious consequences, and it belongs in a conversation with a prescriber before starting rather than after. The related considerations in PCOS and fertility are covered in GLP-1s for women, PCOS and fertility.

The growth hormone axis - a real, mechanistic sex difference

This is the clearest genuinely mechanistic sex difference relevant to peptide therapy, and it is under-discussed.

Growth hormone secretion patterns differ by sex. Women, particularly premenopausal women, secrete GH in a pattern that is on average more continuous and with higher basal levels, while the male pattern is more distinctly pulsatile. More consequentially, oestrogen modulates hepatic IGF-1 generation. Oestrogen - especially oral oestrogen, which undergoes first-pass hepatic metabolism - attenuates GH signalling in the liver, in part through induction of suppressor-of-cytokine-signalling proteins that interfere with the GH receptor's downstream JAK/STAT pathway. The consequence is that for a given amount of GH signal, hepatic IGF-1 output is lower. Transdermal oestrogen, which bypasses first-pass metabolism, has a substantially smaller effect than oral.

Why this matters practically: IGF-1 is the standard biomarker used to interpret response to GHRH analogues and growth hormone secretagogues - most of which are investigational for the uses discussed in this space. If oestrogen status alters the relationship between GH signalling and IGF-1 output, then IGF-1 does not mean the same thing in a woman on oral oestrogen as it does in a man, or as it does in the same woman not on oral oestrogen. Interpreting that number without accounting for oestrogen status is a real interpretive error, not a theoretical one. This is exactly the sort of thing that separates competent monitoring from box-ticking - see peptide therapy biomarkers and optimal versus normal lab ranges.

Endpoints and what "worked" means

The third documented difference is not pharmacological at all, and it is easy to miss.

Trials measure what they were designed to measure. Where the clinical goals and the endpoints chosen differ between populations - lean mass accrual, fat mass reduction, functional capacity, symptom scores, quality-of-life measures - the same compound can produce a "response" that means quite different things. A study reporting a change in lean body mass answers a different question from a study reporting a change in a symptom scale, and comparing across them is not straightforward. When someone says a compound "works for women", the first useful question is: measured how, against what endpoint, in whom.

The honest summary in table form

Where the honest answer is "unknown"

This section is short because there is nothing to report, which is the point.

For the great majority of investigational research peptides - the regenerative and repair-associated compounds, the mitochondrial and longevity-associated compounds, the melanocortin and neuropeptide agents, and the various investigational secretagogues - there is no adequately powered sex-stratified human data. In many cases there is limited human data of any kind, and what exists is small, short and often not randomised. Where animal work exists it frequently used male animals only, which reproduces the same gap one level down.

The correct statement for these is therefore not "they work the same in women" and not "they work differently in women". It is: the question has not been studied at a standard that would support either claim. Anyone asserting a sex-specific effect for one of these compounds is going beyond the published evidence, and it is reasonable to ask them what they are basing it on.

A related caution: "reviewed" is not "approved." A compound that has been examined in a review paper, discussed at an advisory meeting, or characterised in preclinical work has not thereby been shown to be safe or effective in anyone, of either sex. The regulatory status questions are covered in peptide legal status.

Pregnancy and breastfeeding - a hard line

This is the clearest boundary in the article and it does not have a nuanced version.

Safety data in pregnancy and breastfeeding is absent for essentially every compound in this category. Pregnant and breastfeeding women are excluded from the trials, for reasons that are defensible, and the consequence is that there is no evidence base. The critical logical point is that absence of data is not evidence of safety. A compound with no reported harms in pregnancy and a compound with no data in pregnancy look identical in a search result and are entirely different things.

This article offers no reassurance in either direction, because offering reassurance in either direction would require evidence that does not exist. It is a prescriber conversation, and it should happen before conception rather than after a positive test.

Two specific points belong with a prescriber rather than here. GLP-1 receptor agonists carry pre-conception considerations relating to their duration of action, and product labelling in this class addresses discontinuation ahead of a planned pregnancy - the specifics are a prescribing matter and are deliberately not stated here. And the oral-contraceptive absorption interaction noted above has obvious relevance to anyone for whom pregnancy would be unintended.

What this means practically

Three things follow, and none of them is a protocol.

"It's been studied" often means "it's been studied in men." That is a reasonable question to ask about any compound presented as established: studied in whom, how many women, and was the analysis powered to detect a difference. A clinician who can answer that is telling you something useful. One who is irritated by the question is telling you something too.

Thinner evidence is an argument for more monitoring, not less. The intuition sometimes runs the other way - if nothing is known, nothing can be measured. The opposite is true. Where the population-level data does not describe you, individual data becomes proportionally more important, which means baseline measurement and structured follow-up rather than symptom-tracking. The monitoring panels and peptide side effects cover what that involves.

Context changes interpretation. Oestrogen status, cycle phase, hormonal contraception, pregnancy intention, perimenopausal status and menopausal hormone therapy all sit upstream of how a biomarker should be read and of what a compound is likely to do. A clinician who takes that history is doing a different job from one who does not. How to choose a peptide clinic covers what that looks like in practice.

Frequently asked questions

Do peptides work differently in women? For a small number of compounds there is real evidence of differences - the growth hormone axis has a well-characterised oestrogen interaction that changes how IGF-1 should be interpreted, and GLP-1 receptor agonist trials have reported differences between men and women in average weight-loss response and in adverse-event reporting. For the great majority of compounds in this category, the honest answer is that the question has not been studied at a standard capable of supporting an answer in either direction. The general pharmacological differences that exist - body composition, clearance, gastric emptying - are real and would be expected to matter, but "would be expected to matter" is a mechanistic argument, not a finding.

Is dosing different? This article gives no dose figures and no sex-based adjustment guidance, and that is a deliberate limit rather than an omission. What can be said is the underlying principle: weight-flat dosing - administering a fixed amount regardless of body weight - delivers systematically different exposure per kilogram across a range of body weights, and this is a recognised methodological issue in pharmacology. It applies at both extremes of body weight in either sex. It is a reason for the question to be asked properly by someone with prescribing responsibility and access to your measurements and history. It is not a reason for anyone to adjust anything on the basis of an article.

Is any of this actually studied in women specifically? In parts. The GLP-1 obesity programmes enrolled majority-female populations, which makes that the best-characterised area. The oestrogen–IGF-1 relationship is well established in the endocrine literature independently of peptide therapy. Beyond those, sex-stratified data thins out rapidly, and for investigational research peptides it is largely absent - including at the preclinical stage, where male-only animal studies have been common. Reviews across therapeutic areas continue to find that sex-disaggregated reporting is inconsistent, so the absence is a live feature of the field rather than a historical one.

What about pregnancy? Safety data is absent for essentially all of these compounds, and absence of data is not evidence of safety. This article deliberately offers no reassurance in either direction, because the evidence to support reassurance does not exist. Anyone who is pregnant, breastfeeding, planning a pregnancy, or for whom pregnancy is possible should have that conversation with a prescribing clinician before starting anything - and specifically before conception, since GLP-1 receptor agonists carry pre-conception considerations relating to their duration of action, and since delayed gastric emptying can affect the absorption of oral contraceptives.

Related reading

• What are peptides - the category fundamentals this article assumes
• Peptides explained - mechanism and classification, without the marketing
• Peptide therapy biomarkers - including why IGF-1 needs interpreting in context
• Optimal versus normal lab ranges - what a reference range does and does not tell you
• Peptide therapy monitoring panels - what structured follow-up actually covers
• GLP-1s for women, PCOS and fertility - the reproductive-health considerations in more depth
• How to choose a peptide clinic - including what questions reveal whether the evidence gap is understood
• The Complete Guide to Women's Health - the hormonal context that sits upstream of all of this
• Do GLP-1 drugs work better for women than men? - what the 2026 meta-analysis found, and why a group average won't predict your result

Part of The Complete Guide to Peptides.

Educational content, not medical advice. This article contains no doses, no dose figures, no sex-based dosing guidance and no product, brand or compound recommendations, and nothing in it is a recommendation to start, stop or alter any therapy. Compounds described as investigational have not been approved for the uses discussed. There is no safety data supporting the use of these compounds in pregnancy or breastfeeding, and absence of data is not evidence of safety. Any decision about therapy - including any question about how body weight, body composition, oestrogen status or cycle phase should affect it - belongs with a prescribing clinician who has your history and your measurements. Claims for the Malaysian market are subject to MAB requirements.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial.

References

• United States regulatory history on the participation of women in clinical trials: 1977 FDA guidance excluding women of childbearing potential from early-phase studies; 1993 FDA guideline on the study and evaluation of sex differences in the clinical evaluation of drugs; NIH Revitalization Act 1993 requiring inclusion of women in NIH-funded clinical research and analysis by sex.
• Literature on the persistence of inadequate sex-disaggregated reporting and underpowered sex-subgroup analysis in published randomised trials across therapeutic areas.
• FDA drug safety communication, 2013, revising recommended zolpidem dosing for women following data on slower clearance and higher next-morning blood concentrations. (Cited here as regulatory precedent regarding method; no figures reproduced.)
• General sex-differences pharmacology literature: body composition and volume of distribution; average differences in CYP3A4, CYP1A2 and CYP2E1 activity; glomerular filtration rate; gastric emptying rate.
• Pharmacovigilance literature on higher reported adverse drug reaction rates in women, and the unresolved debate over exposure-based, pharmacokinetic and reporting-behaviour explanations.
• GLP-1 receptor agonist obesity trial programmes: majority-female enrolment, and reported sex differences in average percentage weight reduction and in gastrointestinal adverse-event reporting; product labelling addressing the effect of delayed gastric emptying on oral contraceptive absorption, and pre-conception discontinuation considerations relating to duration of action.
• Endocrine literature on sex differences in growth hormone secretory pattern, and on the attenuation of hepatic IGF-1 generation by oestrogen - route-dependent, with oral oestrogen exerting a substantially greater effect than transdermal, via first-pass hepatic exposure and induction of suppressor-of-cytokine-signalling proteins interfering with GH receptor JAK/STAT signalling.
• Literature on the historical predominance of male animals in preclinical research and its consequences for translational sex-difference data.